Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study

20253 citationsJournal Articlehybrid Open Access

Authors

Minghui Zhao · Peking University

Francisco Fidencio Cons Molina · Altoona Arthritis and Osteoporosis Center

Gustavo Aroca · Universidad Simón Bolívar

Maria G. Tektonidou · National and Kapodistrian University of Athens

Anubhav Mathur · Novartis (United States)

Radhika Tangadpalli · Novartis (India)

Rui Sun

Abstract

https://clinicaltrials.gov/study/NCT04181762, NCT04181762 (Novartis study code: CAIN457Q12301). https://www.clinicaltrials.gov/study/NCT05232864, NCT05232864 (Novartis study code: CAIN457Q12301E1).

Topics & Keywords

Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies Chronic Lymphocytic Leukemia Research

Publication Details

Published in: Lara D. Veeken

Volume 65, Issue 1

DOI: 10.1093/rheumatology/keaf536

Field-Weighted Citation Impact: 5.11

Command Palette

Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study

Authors

Abstract

Topics & Keywords

Publication Details